Display options
Cite
Wang SM, Han C, Lee SJ, et al. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016;52(2):91-100doi: 10.4068/cmj.2016.52.2.91.
Wang, S. M., Han, C., Lee, S. J., Patkar, A. A., Masand, P. S., & Pae, C. U. (2016). Vilazodone for the Treatment of Depression: An Update. Chonnam medical journal, 52(2), 91-100. https://doi.org/10.4068/cmj.2016.52.2.91
Wang, Sheng-Min, et al. "Vilazodone for the Treatment of Depression: An Update." Chonnam medical journal vol. 52,2 (2016): 91-100. doi: https://doi.org/10.4068/cmj.2016.52.2.91
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016 May;52(2):91-100. doi: 10.4068/cmj.2016.52.2.91. Epub 2016 May 20. PMID: 27231672; PMCID: PMC4880584.
Copy Download .nbib Format: NLM
Share it on

Chonnam Med J. 2016 May;52(2):91-100. doi: 10.4068/cmj.2016.52.2.91. Epub 2016 May 20.

Vilazodone for the Treatment of Depression: An Update.

Chonnam medical journal

Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae

Affiliations

  1. Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.; International Health Care Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
  2. Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea.
  3. Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.
  4. Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA.
  5. Global Medical Education, New York, NY, USA.
  6. Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.; Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA.

PMID: 27231672 PMCID: PMC4880584 DOI: 10.4068/cmj.2016.52.2.91

Abstract

Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI). We aimed to provide Vilazodone's clinical implications mainly by reviewing published clinical trials. Vilazodone has been speculated to have three potential benefits including faster onset of action, greater efficacy, and better tolerability owning to its SPARI properties. However, no studies conducted so far have directly proven the above speculations. Five initial phase II trials failed to distinguish vilazodone from placebo in the treatment of MDD, but 4 randomized clinical trials (RCT), 3 post-hoc or pooled analysis, 1 long-term open label study, and a meta-analysis showed vilazodone's superior efficacy over placebo. The studies also showed vilazodone is generally safe and tolerable. However, diarrhea, nausea, headache, dizziness, dry mouth, and insomnia warrant close attention in clinical practice because they have been constantly noted throughout the clinical studies. 2 RCTs recently documented the efficacy and safety of vilazodone in patients with generalized anxiety disorder, which could be a start of broadening vilazodone's usage or FDA approval in diverse anxiety disorders.

Keywords: 5-HT1 receptor agonists; Antidepressive agents; Anxiety disorders; Serotonin uptake inhibitors; Vilazodone hydrochloride

References

  1. Pharmacol Ther. 2013 Jan;137(1):119-31 - PubMed
  2. Int J Psychiatry Clin Pract. 2013 Aug;17(3):160-9 - PubMed
  3. Synapse. 1987;1(1):3-9 - PubMed
  4. S Afr Med J. 1997 Apr;87(4 Suppl):534-7, 540 - PubMed
  5. Pharmacol Biochem Behav. 2014 Jun;121:132-7 - PubMed
  6. Int J Clin Pract. 2012 Apr;66(4):356-68 - PubMed
  7. Depress Anxiety. 2015 Jun;32(6):451-9 - PubMed
  8. Core Evid. 2015 Apr 20;10:49-62 - PubMed
  9. CNS Spectr. 2014 Apr;19(2):105-9 - PubMed
  10. CNS Drugs. 2009 Aug;23(8):627-47 - PubMed
  11. Neuropsychopharmacology. 2007 Oct;32(10):2163-72 - PubMed
  12. Am J Psychiatry. 2006 Nov;163(11):1905-17 - PubMed
  13. Br J Pharmacol. 2000 Aug;130(7):1713-9 - PubMed
  14. Int Clin Psychopharmacol. 2015 Nov;30(6):297-306 - PubMed
  15. Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2485-94 - PubMed
  16. Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57 - PubMed
  17. J Sex Med. 2013 Oct;10(10):2465-76 - PubMed
  18. Neuropsychiatr Dis Treat. 2015 Aug 04;11:1957-65 - PubMed
  19. Clin Psychopharmacol Neurosci. 2016 Feb 29;14(1):26-32 - PubMed
  20. Psychiatry Investig. 2015 Apr;12(2):155-63 - PubMed
  21. J Clin Psychiatry. 2009 Mar;70(3):326-33 - PubMed
  22. Br J Pharmacol. 1997 Oct;122(4):733-41 - PubMed
  23. Curr Med Res Opin. 2014 Feb;30(2):263-70 - PubMed
  24. Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84 - PubMed
  25. Psychopharmacology (Berl). 2001 May;155(2):187-92 - PubMed
  26. J Clin Psychopharmacol. 2011 Oct;31(5):643-6 - PubMed
  27. Clin Drug Investig. 2013 Mar;33(3):199-206 - PubMed
  28. BMJ. 2012 Nov 27;345:e7500 - PubMed
  29. J Pharmacol Exp Ther. 1997 Sep;282(3):1581-90 - PubMed
  30. J Clin Psychopharmacol. 2009 Jun;29(3):259-66 - PubMed
  31. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7 - PubMed
  32. Brain Res. 2012 Jun 21;1461:111-8 - PubMed
  33. Nucl Med Biol. 2000 Jul;27(5):429-35 - PubMed
  34. Naunyn Schmiedebergs Arch Pharmacol. 1995 Aug;352(2):141-8 - PubMed
  35. Int Clin Psychopharmacol. 2014 Mar;29(2):86-92 - PubMed
  36. J Psychiatry Neurosci. 2004 Jul;29(4):252-65 - PubMed
  37. Urol Clin North Am. 2007 Nov;34(4):575-9, vii - PubMed
  38. Biol Psychiatry. 2003 Feb 1;53(3):193-203 - PubMed
  39. Int Clin Psychopharmacol. 2015 Mar;30(2):75-81 - PubMed
  40. Am J Ther. 2015 Jul-Aug;22(4):269-77 - PubMed
  41. Psychopharmacology (Berl). 2007 May;192(1):121-33 - PubMed
  42. J Clin Psychiatry. 2011 Sep;72(9):1166-73 - PubMed
  43. Int Clin Psychopharmacol. 2015 Mar;30(2):67-74 - PubMed
  44. Expert Rev Neurother. 2015;15(9):1015-29 - PubMed
  45. J Clin Psychiatry. 2011 Apr;72(4):441-7 - PubMed
  46. Pharmacol Biochem Behav. 2004 Jan;77(1):69-75 - PubMed
  47. Expert Opin Investig Drugs. 2009 Jun;18(6):767-88 - PubMed
  48. J Clin Psychiatry. 2014 Nov;75(11):e1291-8 - PubMed

Publication Types